IsoPlexis bags $25M to stoke T cell therapy buzz; Collaboration between X4 and LLS; New CMO at Precision Biosciences
→ Riding on the buzz around T cell therapies from CAR-T and TCR to CRISPR-based approaches, IsoPlexis has raised $25 million to advance its biomarker-driven system designed to predict responses to such treatments. The Branford, Connecticut-based company works with cancer centers and biopharma companies in the US, Europe and China, applying its single-cell analysis tool to refine their immunotherapies. Northpond Ventures led the Series C, which also featured existing investors Spring Mountain Capital, Ironwood Capital, North Sound Ventures, and Connecticut Innovations.
→ X4 Pharmaceuticals and the Leukemia & Lymphoma Society (LLS) announced their collaboration today to accelerate the development of mavorixafor (X4P-001), X4’s lead product candidate, for the treatment of Waldenström’s macroglobulinemia (WM) — a rare form of non-Hodgkin lymphoma. The company says that under the collaboration, X4 will conduct a multi-national Phase I/II clinical trial — planned to commence this year — to evaluate the safety and assess the preliminary anti-tumor activity of mavorixafor in combination with ibrutinib in WM patients.
LLS CSO Lee Greenberger will serve as an advisory board member for X4 to help provide important strategy and partnership guidance throughout the trial.
→ Christopher Heery has joined Precision BioSciences $DTIL as its new CMO. Heery, an NCI veteran, is moving over from the CMO job at Bavarian Nordic. Earlier he had been head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at NCI.